Home | Welcome to Contract Pharma   
Last Updated Tuesday, May 21 2013
Print RSS Feed

Breaking News

Related Searches: Industry News •
Bilcare GCS Expands Capabilities

November 7, 2008
Bilcare Global Clinical Supplies has enhanced its ability to develop formulation dosage forms for preclinical and early-phase drugs with the addition of fluid bed granulation technology and the In-Cap capsule system.     The fluid b…  Read More »
InNexus Biotechnology Develops New EGFR Antibody

November 7, 2008
InNexus Biotechnology has developed a new antibody product from its DXL platform technology, DXL1218 (EGFR), for the potential treatment of colorectal cancer.     "Recent experimental data suggests that DXL1218 (EGFR) is superi…  Read More »
Financial Report: AMRI 3Q

November 7, 2008
AMRI 3Q Revenues: $61.4 million (+29%) 3Q Earnings: $7.0 million (+250%) YTD Revenues: $172.9 million (+19%) YTD Earnings: $17.4 million (+78%) Comments: Total contract revenue for the quarter was $54.1 million (+30%). Discovery Servi…  Read More »
Pfizer, Sanofi-Aventis End Antiobesity Drug Trials

November 6, 2008
Pfizer is discontinuing the Phase III development program for its investigational compound (CP-945,598) for weight management. CP-945,598 is a selective antagonist of the cannabinoid type 1 (CB1) receptor. The company has decided to discontinue the d…  Read More »
GSK To Cut U.S. Sales Force, Shift U.S. HQ

November 6, 2008
GlaxoSmithKline plans a 12% (or 1,800) reduction in its U.S. sales force as part of a restructuring effort. The company plans to shift some sales representatives from its pharmaceutical unit to its vaccine unit, which will result in a reduction of ab…  Read More »
Patheon Opens Euro HQ in Switzerland

November 6, 2008
Patheon has opened its new headquarters for its European operations in Zug, Switzerland. The new headquarters will manage the company's commercial and pharmaceutical development services sales, marketing and customer support activities in Europe. Cer…  Read More »
Financial Report: Kendle 3Q

November 5, 2008
Kendle 3Q Revenues: $181.1 million (+27%) 3Q Earnings: $11.0 million  (+189%) YTD Revenues: $517.3 million (+25%) YTD Earnings: $24.4 million (+98%) Comments: Early stage revenues were $11.2 million (+138%). Late stage revenues…  Read More »
Financial Report: Hospira 3Q

November 5, 2008
Hospira 3Q Revenues: $925.5 million (+10%) 3Q Earnings: $81.8 million (+38%) YTD Revenues: $2.7 billion (+9%) YTD Earnings: $216.3 million (earnings were $60.7 million YTD07) Comments: Revenue growth in the quarter was driven by strong…  Read More »
Financial Report: Enzon 3Q

November 5, 2008
Enzon 3Q Revenues: $49 million (+4%) 3Q Loss: $2.0 million (earnings were $87.5 million in 3Q07) Comments: Total product sales were $28.9 million in the quarter (+16%) driven by Oncaspar sales, up 19% to $12.5 million. Contract manufacturing…  Read More »
Metrics Opens Expanded Facility

November 4, 2008
Metrics, Inc. has opened a new larger scale manufacturing facility. As part of its expansion, the company has brought online two packaging lines, two granulating rooms and three compressing rooms, including a double-sided, 45-station tablet press. Th…  Read More »
Financial Report: West Pharmaceutical Services

November 4, 2008
West Pharmaceutical Services 3Q Revenues: $256.2 million (+6%) 3Q Earnings: $13.3 million (+9%) YTD Revenues: $806.3 million (+6%) YTD Earnings: $68.3 million (+5%) Comments: Pharmaceutical systems segment sales were $190.5 million (+1…  Read More »
Stora Enso, Medixine Enter Packaging Partnership

November 4, 2008
Stora Enso and Medixine, a health care software provider, have signed an agreement under which the two companies will partner in marketing a new electronic compliance monitoring service. This service is based on Medixine's mobile and server software…  Read More »
Pfizer’s Toviaz Approved for OAB

November 3, 2008
Pfizer received approval from the FDA for Toviaz extended release tablets for the treatment of overactive bladder (OAB) symptoms. The once-daily drug can help regulate the involuntary contractions of the bladder associated with OAB over a period of 2…  Read More »
Halozyme Initiates Phase II Diabetes Trial

November 3, 2008
Halozyme Therapeutics started a Phase II study of recombinant human hyaluronidase enzyme (rHuPH20) co-formulations with Humulin R (regular insulin human injection) and with Humalog (insulin lispro) in Type 1 diabetic patients. This study is designed…  Read More »
Cephalon Gains Additional FDA Approval for Treanda

November 3, 2008
Cephalon, Inc., received approval from the FDA for Treanda for Injection for the treatment of patients with indolent B-cell non-Hodgkin's lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-contai…  Read More »

Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:

Follow Contract Pharma On
Please visit our sister sites: